Page 39 - ESGO - Vulvar cancer - Complete report_fxd2

Original studies presenting response and survival data in patients treated with primary chemoradiation

Authorreference Year N Chemotherapy regimen Radiothera

Han et al.236 2000 LAVC : N = 5-FU 1,000 mg/m² infusion d1-4 + MMC 10 mg/m² IV d1, 45 Gy (vulv
12
given week 1 and 5 of radiotherapy 17 Gy to gro

Berek et al.a,237 1991 LAVC: N = 12 5-FU 1,000 mg/m² infusion d1-4 + CisP 100 mg/m² d1 40-52 Gy in

every 28 d for 2 cycles vulva (up to

Akl et al.239 2000 NA: N = 12 5-FU 1,000 mg/m²/24h as continuous infusion days 1–4 and Vulva only

29-32 + MMC 15 mg/m² IV day 1 Gy daily frac

Thomas et al.230 1989 LAVC: N = 9 5-FU 1,000 mg/m² infusion d1-4 ± MMC 6 mg/m² (4/6 one 40-64 Gy in
injection, and 2/6 two injections 4 weeks apart)

Beriwal et al. 242 2013 LAVC: N = 9 CisP 40 mg/m² d1 (N = 6) and 5-FU 1,000 mg/m² infusion, IMRT 46 G
Mulayim et al.225 2004
d1-5 (N = 36). Two cycles, given the first and last week of 1.8 Gy daily

radiotherapy 1.6 Gy BID f

LAVC : N = 7 5-FU 1,000 mg/m² infusion d1-4 + MMC 10 mg/m² IV d1, 60 Gy for ma
given weeks 1 and 4 of radiotherapy

Evans et al.a,240 1988 LAVC: N = 4 5-FU 1,000 mg/m² continous infusion d1-4 + MMC 10 25-50 Gy in
mg/m² IV d1

Kalra et al.a,241 1985 LAVC: N = 2 MMC 10 mg/m² IV d1 + 5-FU 1,000mg/m² infusion d1-5, 50 Gy in 2 G
given weeks 1 and 4 of radiotherapy

a Radiotherapy given to the vulva, groin and pelvis unless otherwise stated, 5-FU: 5-fluorouracil, Bleo: bleomycin, CR: comp
C, NA: not available, NED: no evidence of disease and no recurrence, PR: partial response, Recurr.: recurrence.

 VULVAR CANCE
39